Trial · NCT07900750
Bwelela Easy Study
NCT07900750, Not applicable, Not yet recruiting, Washington University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bwelela Easy Study. Trials, record NCT07900750. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900750
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bwelela Easy Study
- NCT number
- NCT07900750
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 1,500 participants, estimated
- Lead sponsor
- Washington University School of Medicine
- Conditions
- HIV, HIV - Human Immunodeficiency Virus, Treatment Interruption, Reengagement
- Interventions
Standard of Care - Routine Phone Outreach / Standard of Care - Routine Care and Counseling (SOC-RPO/SOC-RCC), Standard of Care - Routine Phone Outreach / Navigation (SOC-RPO/NAV), Standard of Care - Routine Phone Outreach / Navigation plus Community-Based Medication Delivery (SOC-RPO/NAV+CB-Med), Navigation plus Community-Based Medication Delivery / Standard of Care - Routine Care and Counseling (NAV+CB-Med/SOC-RCC), Navigation plus Community-Based Medication Delivery / Navigation (NAV+CB-Med/NAV), Navigation plus Community-Based Medication Delivery / Navigation plus Community-Based Medication Delivery (NAV+CB-Med/NAV+CB-Med)
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to ART re-initiation (Stage 1) | From initial randomization through end of study follow-up, up to 12 months | Time to confirmed receipt of ART during a return clinic visit or community-based medication delivery by a navigator |
| Primary | Time to Repeat Treatment Interruption after Return (Stage 2) | From Return to Care and Second Stage Randomization to 12 months later | Time to missing a pharmacy refill by \>14 days after return |
| Primary | Proportion of Time Spent in Care and with medications (Stage 1 + Stage 2) | From Treatment Interruption until 18-months | Days spent in care and not \>14 days late for ART pick-up |
| Secondary | Viral Suppression | 12-18 months | Percentage of participants with documented viral suppression, defined as HIV RNA \<400 copies/mL, compared across the six embedded sequential return-and-reengagement strategies. Viral load data are drawn from the national electronic health record (SmartCare), supplemented by field-based viral load collection where necessary. |
| Secondary | Percentage of Participants Engaged in Care 12 to 18 Months After Initial Randomization | 12 to 18 months after initial treatment interruption | |
| Secondary | Time to return for a clinic visit | From initial treatment interruption through end of study follow-up, up to 12 months | Time from initial randomization to first completed HIV clinic visit |
| Secondary | Proportion who return to clinic within 3-months | At 3-months initial treatment interruption | |
| Secondary | Proportion successfully contacted via phone or in-person | At 3-months initial treatment interruption | |
| Secondary | Percent with at least one pharmacy refill missed by >30 days | From second-stage re-randomization up to 12 months | |
| Secondary | Percentage of Participants Attending Any Clinic Visit 6 to 12 Months After Return to Care | 6 to 12 months after return to care |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH135819 | Sequential Strategies to Reach and Reengage Individuals after Lapses from HIV Care in Zambia | MODY, AALOKE | WASHINGTON UNIVERSITY | NATIONAL INSTITUTE OF MENTAL HEALTH | 2024 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900750
GET https://conductscience.org/api/trials/v1/NCT07900750/registered